Condition: Metastatic Breast Cancer · Sponsor: Hellenic Cooperative Oncology Group
Ample evidence has highlighted the significant clinical benefit of novel therapies for many patients with advanced breast cancer (aBC). The use of CDK inhibitors, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and PARP inhibitors as first-line or subsequent treatments has improved progression-free survival (PFS) rates compared to conventional therapies. In selected cases, these treatments have also increased overall survival (OS), reshaping the therapeutic landscape for advanced breast cancer. However, several key questions remain unanswered. For example, what should be the first-line treatment when multiple effective options are available? Determining the optimal sequence of drugs in successive lines of therapy is another major challenge. Furthermore, the development of resistance to treatment and the occurrence of severe adverse events that may lead to early discontinuation or fatal outcomes are pressing concerns. That said, identifying robust predictive biomarkers of response or resistance is crucial for ensuring that patients receive the most effective treatment while avoiding unnecessary exposure to therapies that could cause harm without benefit. Additionally, when multiple effective options exist, selecting the optimal treatment algorithm for each patient based on clinical, pathological, and molecular biomarkers is essential. We herein, aim at employing high throughput methodologies, such as Whole Exome Sequencing, circulating tumour DNA (ctDN…
This description comes directly from the study's public registry record.
Electra Sofou, PhD · +302106912520 · e_sofou@hecog.ondsl.gr
Elena Fountzilas, MD, PhD · +302106912520 · elenafou@gmail.com
Always discuss trial participation with your own doctor first.
| University General Hospital "ATTIKON", 2nd propedeutic dept. of Internal Medicine | Athens, Greece | Recruiting |
| "MITERA" Hospital, Dept. of Medical Oncology | Athens, Greece | Recruiting |
| Metropolitan Hospital, 2nd Dept. of Medical Oncology | Athens, Greece | Recruiting |
| Metropolitan Hospital, 4th Dept. of Medical Oncology | Athens, Greece | Recruiting |
| St. Luke's Hospital, Dept. of Medical Oncology | Thessaloniki, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07066917